The introduction of new vaccines into developing countries

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 646-652

  Mahoney, Richard T ^a,b   Maynard, James E ^c,d  

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

^c PATH   (United States)

^d 4 Nickerson Street 98104   (United States)

Author keywords

Developing countries; Hepatitis B; Vaccine introduction

Indexed keywords

VACCINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEPATITIS B; HUMAN; INTERNATIONAL COOPERATION; LICENSING; MASS COMMUNICATION; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION;

DEVELOPING COUNTRIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INTERNATIONAL COOPERATION;

EID: 0033605095     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00246-1     Document Type: Article

References (17)

1. Homma A. Vaccine self sufficiency in developing countries. Bull. PAHO. 30(2):1996;164-167.
2. W. Muraskin, The War Against Hepatitis B, a History of the International Task Force on Hepatitis B Immunization, University of Pennsylvania Press, Philadelphia, 1995.
3. R.P. Beasley, L.Y. Hwang, C.C. Lin, C.S. Chien, Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan, Lancet 2(8256) (1981) 1129-1133.
4. Global Perspectives on Hepatitis B Immunization, Newsletter, PATH, Seattle, WA.
5. Anonymous, An agenda to expedite global prevention of Haemophilus influenzae type b (Hib) disease, 1st Version, 3 May 1996, Children's Vaccine Initiative, Geneva, Switzerland, 1996.
6. Dienstag J.L. The cost effectiveness of hepatitis B vaccine. J. Infect. 7 (Suppl. 1):1983;81-84.
7. Adler M.W. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br. Med. J. Clin. Res. Ed. 286(6378):1983;1621-1624.
8. D. Lahaye, P. Strauss, C. Baleux, Van W. Ganse, Cost-benefit analysis of hepatitis B vaccination, Lancet 441-443 (1983).
9. Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost effectiveness. Vaccine. 6(4):1988;299-303.
10. Maynard J.E., Kane M.A., Hadler S.C. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Rev. Infect. Dis. 11:1989;S574-S578.
11. World Bank, World Development Report 1993: Investing in Health, World Development Indicators, Oxford University Press, 1993.
12. J. Clemens, R. Brenner, M. Rao, N. Tafari, C. Lowe, Evaluating new vaccine for developing countries: efficacy or effectiveness? JAMA 275(5) (1996).
13. Ruff T.A., Gertig D.M., Otto B.F., Gust I.D., Sutanto A., Soewarso T.I., Kandun N., Marshner I.C., Maynard J.E. Lombok hepatitis B model immunization project: toward universal infant immunization in Indonesia. J. Infect. Dis. 171(2):1995;290-296.
14. Hausdorff W.P. Prospects for the use of new vaccine in developing countries: cost is not the only impediment. Vaccine. 14(13):1996;1179-1186.
15. Batson A., Evans P., Milstien J.B. The crisis in vaccine supply: a framework for action. Vaccine. 12(11):1994;963-965.
16. Hearings Before the Subcommittee on Investigations and General Oversight of the Committee on Labor and Human Resources, United States Senate, 97th Cong., 2nd Sess., Oversight of Immunization Costs, July 22, 1982.
17. CVI Meeting on DTP and DTP Based Combination Vaccines and Polio Eradication, Bandung, Indonesia June 1994 CVI Secretariat/WHO (Draft final Report Oct. 1994).